• Abraham MJ, Murtola T, Schulz R, Pall S, Smith JC, Hess B, Lindahl E. 2015. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1-2: 19-25.

  • Adasme MF, Linnemann KL, Bolz SN, Kaiser F, Salentin S, Haupt VJ, Schroeder M. 2021. PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res, 49: W530-W534.

  • Baldon LVR, de Mendonca SF, Ferreira FV, Rezende FO, Amadou SCG, Leite T, Rocha MN, Marques JT, Moreira LA, Ferreira AGA. 2022. AG129 Mice as a Comprehensive Model for the Experimental Assessment of Mosquito Vector Competence for Arboviruses. Pathogens, 11, 879.

  • Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature, 496: 504-507.

  • Chakraborty S, Alam S, Sayem M, Sanyal M, Das T, Saha P, Sayem M, Byapari BK, Tabassum CT, Kabir A, Amin MR, Nabi A. 2020. Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients - a phase II randomized controlled clinical trial. EClinicalMedicine, 29-30: 100624.

  • Eberhardt J, Santos-Martins D, Tillack AF, Forli S. 2021. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J Chem Inf Model, 61: 3891-3898.

  • Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo JI, Duffy KJ, Jenkins JM. 2009. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells, 27: 424-430.

  • Feng Y. 2024. Recent advances in the study of zika virus structure, drug targets, and inhibitors. Front Pharmacol, 15: 1418516.

  • Imperato PJ. 2016. The Convergence of a Virus, Mosquitoes, and Human Travel in Globalizing the Zika Epidemic. J Community Health, 41: 674-679.

  • Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, Balmaseda A, Harris E. 2017. Antibody-dependent enhancement of severe dengue disease in humans. Science, 358: 929-932.

  • Lee H, Lee J, Hwang J, Park S, Kim N, Kim K, Lee H, Shum D, Jang S. 2021. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. Antibiotics (Basel), 10, 1372.

  • Li Z, Brecher M, Deng YQ, Zhang J, Sakamuru S, Liu B, Huang R, Koetzner CA, Allen CA, Jones SA, Chen H, Zhang NN, Tian M, Gao F, Lin Q, Banavali N, Zhou J, Boles N, Xia M, Kramer LD, Qin CF, Li H. 2017. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Res, 27: 1046-1064.

  • Li Z, Sakamuru S, Huang R, Brecher M, Koetzner CA, Zhang J, Chen H, Qin CF, Zhang QY, Zhou J, Kramer LD, Xia M, Li H. 2018. Erythrosin B is a potent and broad-spectrum orthosteric inhibitor of the flavivirus NS2B-NS3 protease. Antiviral Res, 150: 217-225.

  • Lim SP. 2019. Dengue drug discovery: Progress, challenges and outlook. Antiviral Res, 163: 156-178.

  • Luo D, Vasudevan SG, Lescar J. 2015. The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development. Antiviral Res, 118: 148-158.

  • Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, Pigott DM, Shearer FM, Johnson K, Earl L, Marczak LB, Shirude S, Davis Weaver N, Gilbert M, Velayudhan R, Jones P, Jaenisch T, Scott TW, Reiner RC, Jr., Hay SI. 2019. The current and future global distribution and population at risk of dengue. Nat Microbiol, 4: 1508-1515.

  • Murray NE, Quam MB, Wilder-Smith A. 2013. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol, 5: 299-309.

  • Narayan R, Tripathi S. 2020. Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection. Front Cell Infect Microbiol, 10: 580096.

  • Niu C, Huang Y, Wang M, Huang D, Li J, Huang S, Yang F, Wan C, Zhang R. 2020. Differences in the Transmission of Dengue Fever by Different Serotypes of Dengue Virus. Vector Borne Zoonotic Dis, 20: 143-150.

  • Patkar CG, Kuhn RJ. 2008. Yellow Fever virus NS3 plays an essential role in virus assembly independent of its known enzymatic functions. J Virol, 82: 3342-3352.

  • Paz-Bailey G, Adams LE, Deen J, Anderson KB, Katzelnick LC. 2024. Dengue. Lancet, 403: 667-682.

  • Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH. 1985. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science, 229: 726-733.

  • Saron WAA, Shanmugam K, Tung CC, Patmanathan RK, Rathore APS, Anderson DE, St John AL. 2023. Exacerbated Zika virus-induced neuropathology and microcephaly in fetuses of dengue-immune nonhuman primates. Sci Transl Med, 15: eadd2420.

  • Shukla S, Hong SY, Chung SH, Kim M. 2016. Rapid Detection Strategies for the Global Threat of Zika Virus: Current State, New Hypotheses, and Limitations. Front Microbiol, 7: 1685.

  • Starvaggi J, Previti S, Zappala M, Ettari R. 2024. The Inhibition of NS2B/NS3 Protease: A New Therapeutic Opportunity to Treat Dengue and Zika Virus Infection. Int J Mol Sci, 25, 4376.

  • To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq DJH, Xu M, Wang S, Cameron MD, Heppner DE, Shin BH, Gero TW, Yang A, Dahlberg SE, Wong KK, Eck MJ, Gray NS, Janne PA. 2019. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discov, 9: 926-943.

  • Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. 2005. GROMACS: fast, flexible, and free. J Comput Chem, 26: 1701-1718.

  • Vlachodimitropoulou E, Chen YL, Garbowski M, Koonyosying P, Psaila B, Sola-Visner M, Cooper N, Hider R, Porter J. 2017. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood, 130: 1923-1933.

  • Weaver SC, Reisen WK. 2010. Present and future arboviral threats. Antiviral Res, 85: 328-345.

  • Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O'Brien K, Vannice K, Barrett A, Ferdinand E, Flasche S, Guzman M, Novaes HM, Ng LC, Smith PG, Tharmaphornpilas P, Yoon IK, Cravioto A, Farrar J, Nolan TM. 2019. Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis, 19: e31-e38.

  • World Health O. 2017. Dengue vaccine: WHO position paper, July 2016 - recommendations. Vaccine, 35: 1200-1201.

  • Wu DW, Mao F, Ye Y, Li J, Xu CL, Luo XM, Chen J, Shen X. 2015. Policresulen, a novel NS2B/NS3 protease inhibitor, effectively inhibits the replication of DENV2 virus in BHK-21 cells. Acta Pharmacol Sin, 36: 1126-1136.

  • Zephyr J, Rao DN, Johnson C, Shaqra AM, Nalivaika EA, Jordan A, Kurt Yilmaz N, Ali A, Schiffer CA. 2023. Allosteric quinoxaline-based inhibitors of the flavivirus NS2B/NS3 protease. Bioorg Chem, 131: 106269.

  • Zhang Y, Kolesar JM. 2011. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura. Clin Ther, 33: 1560-1576.